Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, consider the potential implications of ongoing and planned clinical trials using PARP inhibitors in combination with other therapies to treat men with prostate cancer including:
Karim Fizazi, MD, PhD
Institut Gustave Roussey
Joaquin Mateo, MD, PhD
Vall d’Hebron University Hospital,
Updated analysis of rate of bone fractures in phase III EORTC GUCG 1333/PEACE-3 trial with or without BPAs from ASCO 2021, as reported by Clinical Care Options (CCO)
Downloadable slideset covering PARP inhibitor monotherapy and determinants of response in metastatic CRPC, from Clinical Care Options (CCO)
Downloadable slideset reviewing the rationale for PARP inhibitor combinations in metastatic CRPC, from Clinical Care Options (CCO)
Results of phase III VISION trial with 177Lu-PSMA-617 + SOC vs SOC in metastatic castration-resistant prostate cancer from ASCO 2021, as reported by Clinical Care Options (CCO)